ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference [Yahoo! Finance]
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Yahoo! Finance
Morgan conference led by CEO Jason Lettmann and Chief Medical Officer Barbara Klencke. Management highlighted what it described as an “incredible year” of multiple data readouts and said it is now focusing evorpacept development in HER2-positive breast cancer and multiple myeloma, while advancing ALX2004 through early dose escalation in a first-in-human Phase 1 study. ? Why Apple Chose Google to Power the Future of AI Lettmann framed CD47 as an important but historically difficult immuno-oncology target, noting that many prior programs were discontinued due to therapeutic window challenges. He said ALX Oncology's approach is differentiated because evorpacept blocks the “don't-eat-me” signal (CD47) while relying on a separate Fc-active antibody (such as a standard anticancer antibody or a bispecific) to provide the “eat-me” signal. According to the company, this bifurcated mechanism avoids activating macrophages against red blood cells, enabling higher dosing without the on-targe
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks [Yahoo! Finance]Yahoo! Finance
- ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004GlobeNewswire
- ALX Oncology (NASDAQ:ALXO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ALXO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</MarketBeat
- ALX Oncology (NASDAQ:ALXO) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ALXO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZenMarketBeat
ALXO
Earnings
- 11/7/25 - Miss
ALXO
Sec Filings
- 1/7/26 - Form 4
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- ALXO's page on the SEC website